XRCC1

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy

L. Zhang, Ma, W., Li, Y., Wu, J., and Shi, G. Y., Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy, vol. 13, pp. 228-236, 2014.

Individual differences in chemosensitivity and clinical outcome of non-small-cell lung carcinoma (NSCLC) patients can be influenced by host-inherited factors. We investigated the impact of XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp, and XPD Lys751Gln gene polymorphisms on treatment efficacy in 375 NSCLC patients on platinum-based chemotherapy. We also examined progression-free survival and overall survival. The gene polymorphisms were analyzed by duplex PCR.

Association study of c.910A>G and c.1686C>G polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in the Chinese population

W. F. Xia, Ma, X. P., Li, X. R., Dong, H., and Yi, J. L., Association study of c.910A>G and c.1686C>G polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in the Chinese population, vol. 13, pp. 1314-1322, 2014.

XRCC1 (human X-ray repair complementing defective repair in Chinese hamster cell 1) gene is considered a potentially important gene influencing the risk of hepatocellular carcinoma (HCC). Our analyses detected two allelic variants of XRCC1, c.910A>G and c.1686C>G. We aimed to investigate whether these polymorphisms influence the risk of HCC. The association between the XRCC1 polymorphisms and the risk of HCC was analyzed in 719 patients and 662 controls by polymerase chain reaction-restriction fragment length polymorphism.

Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis

J. Xu, Ma, J., Zong, H. T., Wang, S. Y., and Zhou, J. W., Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis, vol. 13, pp. 1438-1446, 2014.

It is still controversial whether X-ray repair cross-complementing group (XRCC1) gene polymorphisms (Arg194Trp and Arg399Gln) are associated with the clinical outcome of platinum-based chemotherapy in gastric cancer patients based on published studies. Meta-analysis was performed to provide a systematic review of the findings. Eligible articles from the PubMed, SinoMed, and CNKI databases before September 1, 2012, were selected.

Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer

D. Liu, Wu, J., Shi, G. Y., Zhou, H. F., and Yu, Y., Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer, vol. 13, pp. 3100-3107, 2014.

We aimed to assess the role of polymorphisms of the XRCC1 Arg194Trp, XRCC1 Arg399Gln, ERCC5 His1104Asp, and ERCC5 His46His genes on clinical outcomes of advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy regimens. A total of 378 NSCLC patients were asked to participate within 1 month after diagnosis between January 2005 and January 2006, and they were followed up until November 2011. Genomic DNA of the four genes was extracted using the Qiagen Blood Kit.

Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis

L. Li, Wan, C., and Wen, F. Q., Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis, vol. 13, pp. 3772-3786, 2014.

X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and response rate of platinum chemotherapy in advanced NSCLC patients.

Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma

J. S. Wu, Chen, Y. P., Wang, L. C., Yang, Y. J., Deng, C. W., Hou, B. X., He, Z. L., and Chen, J. X., Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma, vol. 13, pp. 3812-3818, 2014.

We explored the association between 4 XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms with the development and prognosis of hepatocellular carcinoma (HCC). A total of 218 cases with HCC and 277 healthy controls were included in the study. Genotyping of the XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms was performed in a 384-well plate format on the Sequenom MassARRAY platform.

Association between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk

B. B. Sun, Wu, J. Z., Li, Y. G., and Ma, L. J., Association between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk, vol. 13, pp. 10223-10230, 2014.

Numerous studies have evaluated the association between the X-ray repair cross-complementing group 1 (XRCC1) DNA repair gene polymorphism -77T>C and lung cancer risk. However, this association is controversial. We used PubMed and Embase to identify 5 case-control studies, which included 2488 lung cancer cases and 2576 controls, for inclusion in a comprehensive meta-analysis in order to assess this association. Two independent reviewers extracted data from the studies, and ORs with 95%CIs were calculated.

Lack of an association between the XRCC1 Arg399Gln polymorphism and gastric cancer based on a meta-analysis

B. M. Liu, Liu, T. M., You, B. S., You, H. Y., Yang, J., Li, L., and He, Y. C., Lack of an association between the XRCC1 Arg399Gln polymorphism and gastric cancer based on a meta-analysis, vol. 11, pp. 3852-3860, 2012.

Association between the XRCC1 Arg399Gln polymorphism and susceptibility to gastric cancer has been investigated; overall, the results have been inconclusive. We made a meta-analysis of 13 case-control studies, including 3278 cases and 6243 controls. Crude odds ratios (OR) with 95% confidence intervals (95%CI) were used to assess this possible association.

Meta-analysis demonstrates lack of a relationship between XRCC1-399 gene polymorphisms and susceptibility to hepatocellular carcinoma

X. Y. Zeng, Huang, J. M., Xu, J. W., Xu, Y., Yu, H. P., Ji, L., and Qiu, X. Q., Meta-analysis demonstrates lack of a relationship between XRCC1-399 gene polymorphisms and susceptibility to hepatocellular carcinoma, vol. 12, pp. 1916-1923, 2013.

XRCC1-399 allele polymorphisms have been reported to be associated with susceptibility to hepatocellular carcinoma (HCC), but the conclusions of the various studies have been inconsistent. We conducted a meta-analysis of available studies to determine whether XRCC1-399 alleles influence susceptibility to hepatocellular carcinoma.

Analysis of the polymorphisms XRCC1Arg194Trp and XRCC1Arg399Gln in gliomas

A. C. Custódio, Almeida, L. O., Pinto, G. R., Santos, M. J., Almeida, J. R. W., Clara, C. A., Rey, J. A., and Casartelli, C., Analysis of the polymorphisms XRCC1Arg194Trp and XRCC1Arg399Gln in gliomas, vol. 10, pp. 1120-1129, 2011.

XRCC genes (X-ray cross-complementing group) were discovered mainly for their roles in protecting mammalian cells against damage caused by ionizing radiation. Studies determined that these genes are important in the genetic stability of DNA. Although the loss of some of these genes does not necessarily confer high levels of sensitivity to radiation, they have been found to represent important components of various pathways of DNA repair. To ensure the integrity of the genome, a complex system of DNA repair was developed.

Pages

Subscribe to XRCC1